Information Provided By: 
Fly News Breaks for February 20, 2018
NVAX
Feb 20, 2018 | 06:22 EDT
Citi analyst Joel Beatty raised his price target for Novavax to $2.75 after increasing the value attributed to the company's respiratory syncytial virus vaccine. Even with the stock rallying 80% since last month, the analyst believes Novavax's RSV vaccine is still underappreciated by the Street. Beatty, however, maintains a Neutral rating on the shares ahead of the Phase 1/2 NanoFlu vaccine data expected by the end of February.
News For NVAX From the Last 2 Days
There are no results for your query NVAX
